NCT05636501

Treat-to-target Prednisolon Taper in Patients With Polymyalgia Rheumatica

Dose Reduction and Discontinuation of Prednisolone Using Structured Treat-to-target Taper in Patients With Polymyalgia Rheumatica

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Aarhus University Hospital · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Polymyalgia rheumatica (PMR) has an incidence of approximately 1000/10\^6 for persons more than 50 years. Treatment with prednisolone carries several significant adverse effects, and it is therefore essential to taper prednisolone as fast as possible. Systematic treatment strategies (treat-to-target) is the most important improvement of disease management for other rheumatic diseases such as rheumatoid arthritis in the last decades. Thus, the purpose is to investigate benefits and harms associated with a nurce led systematic prednisolone taper strategy at the department of rheumatology compared to individual treatment by discretion of the general practitioner. It is a 1-year open label randomised trial with a 1-year extension in 120 treatment naïve patients with PMR.

Conditions

• Polymyalgia Rheumatica

Interventions

Type	Name	Description
OTHER	Treat-to-target Prednisolone Taper	Systematic prednisolone taper
OTHER	Usual care	Prednisolone taper performed by discretion of the patient's general practitioner.

Timeline

• Start date: 2023-01-12
• Primary completion: 2025-10-09
• Completion: 2026-11-01
• First posted: 2022-12-05
• Last updated: 2025-12-18

Locations

6 sites across 1 country: Denmark